TOP2A and neoplasm: Since we found that knockdown of UBE2C reduced the expression of TOP2A, we speculated that inhibiting UBE2C might have a synergistic effect with doxorubicin, enhancing its ability to inhibit TOP2A expression and reach a better anti‐tumor effect.